FDA label 30d883a9-da26-192f-e054-00144ff88e88
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- SPL set ID
- 1d5a88eb-1aa1-4cfa-837b-7477bc36c383
- SPL ID
- 30d883a9-da26-192f-e054-00144ff88e88
- Version
- 2
- Effective date
- 2016-04-19
- Source export date
- 2026-11-13
- Source partition
- 10
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0010-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/829e43b83940afb8dda22d5287c5b17e57d3fe45d1157678854b4f9b7ad07271/drug-label-0010-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 17:22:08
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| spl id | 30d883a9-da26-192f-e054-00144ff88e88 | id | |
| spl set id | 1d5a88eb-1aa1-4cfa-837b-7477bc36c383 | set_id |
Boxed warning cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
BOXED WARNING Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. INVEGA ® (paliperidone) Extended-Release Tablets is not approved for the treatment of patients with dementia-related psychosis. [see Warnings and Precautions (5.1) ]
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
warnings and cautions table
<table width="90%"> <caption>Table 2b. Change in Fasting Lipids from a Placebo-Controlled 6-Week Study in Adolescent Subjects (12–17 years of age) with Schizophrenia</caption> <col span="1" align="left" valign="bottom" width="30%"/> <col span="1" align="center" valign="middle" width="14%"/> <col span="1" align="center" valign="middle" width="14%"/> <col span="1" align="center" valign="middle" width="14%"/> <col span="1" align="center" valign="middle" width="14%"/> <col span="1" align="center" valign="middle" width="14%"/> <tbody> <tr> <th colspan="1"/> <th colspan="1"/> <th colspan="4"> INVEGA <sup>®</sup> </th> </tr> <tr> <th colspan="1"/> <th colspan="1">Placebo</th> <th colspan="1">1.5 mg/day</th> <th colspan="1">3 mg/day</th> <th colspan="1">6 mg/day</th> <th colspan="1">12 mg/day</th> </tr> <tr> <td/> <td> <content styleCode="bold">Mean change from baseline (mg/dL)</content> </td> </tr> <tr> <td> <content styleCode="bold">Cholesterol</content> </td> <td> <content styleCode="bold">n=39</content> </td> <td> <content styleCode="bold">n=45</content> </td> <td> <content styleCode="bold">n=11</content> </td> <td> <content styleCode="bold">n=28</content> </td> <td> <content styleCode="bold">n=32</content> </td> </tr> <tr> <td> <content styleCode="bold">Change from baseline</content> </td> <td>-7.8</td> <td>-3.3</td> <td>12.7</td> <td>3.0</td> <td>-1.5</td> </tr> <tr> <td> <content styleCode="bold">LDL</content> </td> <td> <content styleCode="bold">n=37</content> </td> <td> <content styleCode="bold">n=40</content> </td> <td> <content styleCode="bold">n=9</content> </td> <td> <content styleCode="bold">n=27</content> </td> <td> <content styleCode="bold">n=31</content> </td> </tr> <tr> <td> <content styleCode="bold"> Change from baseline</content> </td> <td>-4.1</td> <td>-3.1</td> <td>7.2</td> <td>2.4</td> <td>0.6</td> </tr> <tr> <td> <content styleCode="bold">HDL</content> </td> <td> <content styleCode="bold">n=37</content> </td> <td> <content styleCode="bold">n=41</content> </td> <td> <content styleCode="bold">n=9</content> </td> <td> <content styleCode="bold">n=27</content> </td> <td> <content styleCode="bold">n=31</content> </td> </tr> <tr> <td> <content styleCode="bold">Change from baseline</content> </td> <td>-1.9</td> <td>0.0</td> <td>1.3</td> <td>1.4</td> <td>0.0</td> </tr> <tr> <td> <content styleCode="bold">Triglycerides</content> </td> <td> <content styleCode="bold">n=39</content> </td> <td> <content styleCode="bold">n=44</content> </td> <td> <content styleCode="bold">n=11</content> </td> <td> <content styleCode="bold">n=28</content> </td> <td> <content styleCode="bold">n=32</content> </td> </tr> <tr> <td> <content styleCode="bold"> Change from baseline</content> </td> <td>-8.9</td> <td>3.2</td> <td>17.6</td> <td>-5.4</td> <td>3.9</td> </tr> <tr> <td/> <td> <content styleCode="bold">Proportion of Patients with Shifts</content> </td> </tr> <tr> <td> <content styleCode="bold">Cholesterol</content> </td> <td/> <td/> <td/> <td/> <td/> </tr> <tr> <td> <content styleCode="bold">Normal to High</content> </td> <td>7%</td> <td>4%</td> <td>0%</td> <td>6%</td> <td>11%</td> </tr> <tr> <td> <content styleCode="bold">(<170 mg/dL to ≥200 mg/dL)</content> </td> <td>(2/27)</td> <td>(1/26)</td> <td>(0/6)</td> <td>(1/18)</td> <td>(2/19)</td> </tr> <tr> <td> <content styleCode="bold">LDL</content> </td> <td/> <td/> <td/> <td/> <td/> </tr> <tr> <td> <content styleCode="bold">Normal to High</content> </td> <td>3%</td> <td>4%</td> <td>14%</td> <td>0%</td> <td>9%</td> </tr> <tr> <td> <content styleCode="bold">(<110 mg/dL to ≥130 mg/dL)</content> </td> <td>(1/32)</td> <td>(1/25)</td> <td>(1/7)</td> <td>(0/22)</td> <td>(2/22)</td> </tr> <tr> <td> <content styleCode="bold">HDL</content> </td> <td/> <td/> <td/> <td/> <td/> </tr> <tr> <td> <content styleCode="bold">Normal to Low</content> </td> <td>14%</td> <td>7%</td> <td>29%</td> <td>13%</td> <td>23%</td> </tr> <tr> <td> <content styleCode="bold">( ≥40 mg/dL to <40 mg/dL)</content> </td> <td>(4/28)</td> <td>(2/30)</td> <td>(2/7)</td> <td>(3/23)</td> <td>(5/22)</td> </tr> <tr> <td> <content styleCode="bold">Triglycerides</content> </td> <td/> <td/> <td/> <td/> <td/> </tr> <tr> <td> <content styleCode="bold"> Normal to High</content> </td> <td>3%</td> <td>5%</td> <td>13%</td> <td>8%</td> <td>7%</td> </tr> <tr> <td> <content styleCode="bold">(<150 mg/dL to ≥200 mg/dL)</content> </td> <td>(1/34)</td> <td>(2/38)</td> <td>(1/8)</td> <td>(2/26)</td> <td>(2/28)</td> </tr> </tbody> </table>
warnings and cautions table
<table width="90%"> <caption>Table 3a. Mean Change in Body Weight (kg) and the Proportion of Subjects with ≥ 7% Gain in Body Weight from Three Placebo-Controlled, 6-Week, Fixed-Dose Studies in Adult Subjects with Schizophrenia</caption> <col span="1" align="left" valign="bottom" width="30%"/> <col span="1" align="center" valign="bottom" width="14%"/> <col span="1" align="center" valign="bottom" width="14%"/> <col span="1" align="center" valign="bottom" width="14%"/> <col span="1" align="center" valign="bottom" width="14%"/> <col span="1" align="center" valign="bottom" width="14%"/> <tbody> <tr> <th colspan="1"/> <th colspan="1"/> <th colspan="4">INVEGA <sup>®</sup> </th> </tr> <tr> <th colspan="1"/> <th colspan="1">Placebo</th> <th colspan="1">3 mg/day</th> <th colspan="1">6 mg/day</th> <th colspan="1">9 mg/day</th> <th colspan="1">12 mg/day</th> </tr> <tr> <th colspan="1"/> <th colspan="1">n=323</th> <th colspan="1">n=112</th> <th colspan="1">n=215</th> <th colspan="1">n=235</th> <th colspan="1">n=218</th> </tr> <tr> <td> <content styleCode="bold">Weight (kg) Change from baseline </content> </td> <td>-0.4</td> <td>0.6</td> <td>0.6</td> <td>1.0</td> <td>1.1</td> </tr> <tr> <td> <content styleCode="bold">Weight Gain ≥ 7% increase from baseline </content> </td> <td>5%</td> <td>7%</td> <td>6%</td> <td>9%</td> <td>9%</td> </tr> </tbody> </table>
warnings and cautions table
<table width="90%"> <caption>Table 3b. Mean Change in Body Weight (kg) and the Proportion of Subjects with ≥ 7% Gain in Body Weight from a Placebo-Controlled 6-Week Study in Adolescent Subjects (12–17 years of age) with Schizophrenia</caption> <col span="1" align="left" valign="bottom" width="30%"/> <col span="1" align="center" valign="bottom" width="14%"/> <col span="1" align="center" valign="bottom" width="14%"/> <col span="1" align="center" valign="bottom" width="14%"/> <col span="1" align="center" valign="bottom" width="14%"/> <col span="1" align="center" valign="bottom" width="14%"/> <tbody> <tr> <th colspan="1"/> <th colspan="1"/> <th colspan="4">INVEGA <sup>®</sup> </th> </tr> <tr> <th colspan="1"/> <th colspan="1">Placebo</th> <th colspan="1">1.5 mg/day</th> <th colspan="1">3 mg/day</th> <th colspan="1">6 mg/day</th> <th colspan="1">12 mg/day</th> </tr> <tr> <th colspan="1"/> <th colspan="1">n=51</th> <th colspan="1">n=54</th> <th colspan="1">n=16</th> <th colspan="1">n=45</th> <th colspan="1">n=34</th> </tr> <tr> <td> <content styleCode="bold">Weight (kg) Change from baseline </content> </td> <td>0.0</td> <td>0.3</td> <td>0.8</td> <td>1.2</td> <td>1.5</td> </tr> <tr> <td> <content styleCode="bold">Weight Gain ≥ 7% increase from baseline </content> </td> <td>2%</td> <td>6%</td> <td>19%</td> <td>7%</td> <td>18%</td> </tr> </tbody> </table>
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
ADVERSE REACTIONS Commonly observed adverse reactions (incidence ≥ 5% and at least twice that for placebo) were ( 6 ) Adults with schizophrenia: extrapyramidal symptoms, tachycardia, and akathisia. Adolescents with schizophrenia: somnolence, akathisia, tremor, dystonia, cogwheel rigidity, anxiety, weight increased, and tachycardia. Adults with schizoaffective disorder: extrapyramidal symptoms, somnolence, dyspepsia, constipation, weight increased, and nasopharyngitis. To report SUSPECTED ADVERSE REACTIONS, contact Janssen Pharmaceuticals, Inc. at 1-800-JANSSEN (1-800-526-7736) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch The following adverse reactions are discussed in more detail in other sections of the labeling: Increased mortality in elderly patients with dementia-related psychosis [see Boxed Warning and Warnings and Precautions (5.1) ] Cerebrovascular adverse reactions, including stroke, in elderly patients with dementia-related psychosis [see Warnings and Precautions (5.2) ] Neuroleptic malignant syndrome [see Warnings and Precautions (5.3) ] QT prolongation [see Warnings and Precautions (5.4) ] Tardive dyskinesia [see Warnings and Precautions (5.5) ] Metabolic changes [see Warnings and Precautions (5.6) ] Hyperprolactinemia [see Warnings and Precautions (5.7) ] Potential for gastrointestinal obstruction [see Warnings and Precautions (5.8) ] Orthostatic hypotension and syncope [see Warnings and Precautions (5.9) ] Leukopenia, neutropenia, and agranulocytosis [see Warnings and Precautions (5.10) ] Potential for cognitive and motor impairment [see Warnings and Precautions (5.11) ] Seizures [see Warnings and Precautions (5.12) ] Dysphagia [see Warnings and Precautions (5.13) ] Suicide [see Warnings and Precautions (5.14) ] Priapism [see Warnings and Precautions (5.15) ] Thrombotic thrombocytopenic purpura (TTP) [see Warnings and Precautions (5.16) ] Disruption of body temperature regulation [see Warnings and Precautions (5.17) ] Antiemetic effect [see Warnings and Precautions (5.18) ] Increased sensitivity in patients with Parkinson's disease or those with dementia with Lewy bodies [see Warnings and Precautions (5.19) ] Diseases or conditions that could affect metabolism or hemodynamic responses [see Warnings and Precautions (5.19) ] The most common adverse reactions in clinical trials in adult subjects with schizophrenia (reported in 5% or more of subjects treated with INVEGA ® and at least twice the placebo rate in any of the dose groups) were extrapyramidal symptoms, tachycardia, and akathisia. The most common adverse reactions in clinical trials in adult patients with schizoaffective disorder (reported in 5% or more of subjects treated with INVEGA ® and at least twice the placebo rate) were extrapyramidal symptoms, somnolence, dyspepsia, constipation, weight increased, and nasopharyngitis. The most common adverse reactions that were associated with discontinuation from clinical trials in adult subjects with schizophrenia (causing discontinuation in 2% of INVEGA ® -treated subjects) were nervous system disorders. The most common adverse reactions that were associated with discontinuation from clinical trials in adult subjects with schizoaffective disorder were gastrointestinal disorders, which resulted in discontinuation in 1% of INVEGA ® -treated subjects. [See Adverse Reactions (6.4) ] . The safety of INVEGA ® was evaluated in 1205 adult subjects with schizophrenia who participated in three placebo-controlled, 6-week, double-blind trials, of whom 850 subjects received INVEGA ® at fixed doses ranging from 3 mg to 12 mg once daily. The information presented in this section was derived from pooled data from these three trials. Additional safety information from the placebo-controlled phase of the long-term maintenance study, in which subjects received INVEGA ® at daily doses within the range of 3 mg to 15 mg (n=104), is also included. The safety of INVEGA ® was evaluated in 150 adolescent subjects 12–17 years of age with schizophrenia who received INVEGA ® in the dose range of 1.5 mg to 12 mg/day in a 6-week, double-blind, placebo-controlled trial. The safety of INVEGA ® was also evaluated in 622 adult subjects with schizoaffective disorder who participated in two placebo-controlled, 6-week, double-blind trials. In one of these trials, 206 subjects were assigned to one of two dose levels of INVEGA ® : 6 mg with the option to reduce to 3 mg (n = 108) or 12 mg with the option to reduce to 9 mg (n = 98) once daily. In the other study, 214 subjects received flexible doses of INVEGA ® (3–12 mg once daily). Both studies included subjects who received INVEGA ® either as monotherapy or as an adjunct to mood stabilizers and/or antidepressants. Adverse events during exposure to study treatment were obtained by general inquiry and recorded by clinical investigators using their own terminology. Consequently, to provide a meaningful estimate of the proportion of individuals experiencing adverse events, events were grouped in standardized categories using MedDRA terminology. Throughout this section, adverse reactions are reported. Adverse reactions are adverse events that were considered to be reasonably associated with the use of INVEGA ® (adverse drug reactions) based on the comprehensive assessment of the available adverse event information. A causal association for INVEGA ® often cannot be reliably established in individual cases. Further, because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. Adult Patients with Schizophrenia Table 4 enumerates the pooled incidences of adverse reactions reported in the three placebo-controlled, 6-week, fixed-dose studies in adults, listing those that occurred in 2% or more of subjects treated with INVEGA ® in any of the dose groups, and for which the incidence in INVEGA ® -treated subjects in any of the dose groups was greater than the incidence in subjects treated with placebo. Table 4. Adverse Reactions Reported by ≥ 2% of INVEGA ® -Treated Adult Subjects with Schizophrenia in Three Short-Term, Fixed-Dose, Placebo-Controlled Clinical Trials * Percentage of Patients INVEGA ® Placebo 3 mg once daily 6 mg once daily 9 mg once daily 12 mg once daily Body System or Organ Class (N=355) (N=127) (N=235) (N=246) (N=242) Dictionary-Derived Term Total percentage of subjects with adverse reactions 37 48 47 53 59 Cardiac disorders Atrioventricular block first degree 1 2 0 2 1 Bundle branch block 2 3 1 3 <1 Sinus arrhythmia 0 2 1 1 <1 Tachycardia 7 14 12 12 14 Gastrointestinal disorders Abdominal pain upper 1 1 3 2 2 Dry mouth 1 2 3 1 3 Salivary hypersecretion <1 0 <1 1 4 General disorders Asthenia 1 2 <1 2 2 Fatigue 1 2 1 2 2 Nervous system disorders Akathisia 4 4 3 8 10 Dizziness 4 6 5 4 5 Extrapyramidal symptoms 8 10 7 20 18 Headache 12 11 12 14 14 Somnolence 7 6 9 10 11 Vascular disorders Orthostatic hypotension 1 2 1 2 4 Table includes adverse reactions that were reported in 2% or more of subjects in any of the INVEGA Adolescent Patients with Schizophrenia Table 5 lists the adverse reactions reported in a fixed-dose, placebo-controlled study in adolescent subjects 12–17 years of age with schizophrenia, listing those that occurred in 2% or more of subjects treated with INVEGA ® in any of the dose groups, and for which the incidence in INVEGA ® -treated subjects in any of the dose groups was greater than the incidence in subjects treated with placebo. Table 5. Adverse Reactions Reported by ≥ 2% of INVEGA ® -Treated Adolescent Subjects with Schizophrenia in a Fixed-Dose, Placebo-Controlled Clinical Trial * Percentage of Patients INVEGA ® Placebo 1.5 mg once daily 3 mg once daily 6 mg once daily 12 mg once daily Body System or Organ Class (N=51) (N=54) (N=16) (N=45) (N=35) Dictionary-Derived Term Total percentage of subjects with adverse reactions 43 37 50 58 74 Cardiac disorders Tachycardia 0 0 6 9 6 Eye disorders Vision blurred 0 0 0 0 3 Gastrointestinal disorders Dry mouth 2 0 0 0 3 Salivary hypersecretion 0 2 6 2 0 Swollen tongue 0 0 0 0 3 Vomiting 10 0 6 11 3 General disorders Asthenia 0 0 0 2 3 Fatigue 0 4 0 2 3 Infections and infestations Nasopharyngitis 2 4 0 4 0 Investigations Weight increased 0 7 6 2 3 Nervous system disorders Akathisia 0 4 6 11 17 Dizziness 0 2 6 2 3 Extrapyramidal symptoms 0 4 19 18 23 Headache 4 9 6 4 14 Lethargy 0 0 0 0 3 Somnolence 4 9 13 20 26 Tongue paralysis 0 0 0 0 3 Psychiatric disorders Anxiety 4 0 0 2 9 Reproductive system and breast disorders Amenorrhea 0 0 6 0 0 Galactorrhea 0 0 0 4 0 Gynecomastia 0 0 0 0 3 Respiratory, thoracic and mediastinal disorders Epistaxis 0 0 0 2 0 Table includes adverse reactions that were reported in 2% or more of subjects in any of the INVEGA Table 6 enumerates the pooled incidences of adverse reactions reported in the two placebo-controlled 6-week studies in adult subjects, listing those that occurred in 2% or more of subjects treated with INVEGA ® and for which the incidence in INVEGA ® -treated subjects was greater than the incidence in subjects treated with placebo. Table 6. Adverse Drug Reactions Reported by ≥ 2% of INVEGA ® -Treated Adult Subjects with Schizoaffective Disorder in Two Double-Blind, Placebo-Controlled Clinical Trials * Percentage of Patients INVEGA ® INVEGA ® INVEGA ® Placebo 3–6 mg once-daily fixed-dose range 9–12 mg once-daily fixed-dose range 3–12 mg once-daily flexible dose Body System or Organ Class (N=202) (N=108) (N=98) (N=214) Dictionary-Derived Term Total percentage of subjects with adverse reactions 32 48 50 43 Cardiac disorders Tachycardia 2 3 1 2 Gastrointestinal disorders Abdominal discomfort/Abdominal pain upper 1 1 0 3 Constipation 2 4 5 4 Dyspepsia 2 5 6 6 Nausea 6 8 8 5 Stomach discomfort 1 0 1 2 General disorders Asthenia 1 3 4 <1 Infections and Infestations Nasopharyngitis 1 2 5 3 Rhinitis 0 1 3 1 Upper respiratory tract infection 1 2 2 2 Investigations Weight increased 1 5 4 4 Metabolism and nutrition disorders Decreased appetite <1 1 0 2 Increased appetite <1 3 2 2 Musculoskeletal and connective tissue disorders Back pain 1 1 1 3 Myalgia <1 2 4 1 Nervous system disorders Akathisia 4 4 6 6 Dysarthria 0 1 4 2 Extrapyramidal symptoms 8 20 17 12 Somnolence 5 12 12 8 Psychiatric disorders Sleep disorder <1 2 3 0 Respiratory, thoracic and mediastinal disorders Cough 1 1 3 1 Pharyngolaryngeal pain <1 0 2 1 Table includes adverse reactions that were reported in 2% or more of subjects in any of the INVEGA Monotherapy versus Adjunctive Therapy The designs of the two placebo-controlled, 6-week, double-blind trials in adult subjects with schizoaffective disorder included the option for subjects to receive antidepressants (except monoamine oxidase inhibitors) and/or mood stabilizers (lithium, valproate, or lamotrigine). In the subject population evaluated for safety, 230 (55%) subjects received INVEGA ® as monotherapy and 190 (45%) subjects received INVEGA ® as an adjunct to mood stabilizers and/or antidepressants. When comparing these 2 subpopulations, only nausea occurred at a greater frequency (≥ 3% difference) in subjects receiving INVEGA ® as monotherapy. Schizophrenia Trials The percentages of subjects who discontinued due to adverse reactions in the three schizophrenia placebo-controlled, 6-week, fixed-dose studies in adults were 3% and 1% in INVEGA ® - and placebo-treated subjects, respectively. The most common reasons for discontinuation were nervous system disorders (2% and 0% in INVEGA ® - and placebo-treated subjects, respectively). Among the adverse reactions in the 6-week, fixed-dose, placebo-controlled study in adolescents with schizophrenia, only dystonia led to discontinuation (<1% of INVEGA ® -treated subjects). Schizoaffective Disorder Trials The percentages of subjects who discontinued due to adverse reactions in the two schizoaffective disorder placebo-controlled 6-week studies in adults were 1% and <1% in INVEGA ® - and placebo-treated subjects, respectively. The most common reasons for discontinuation were gastrointestinal disorders (1% and 0% in INVEGA ® - and placebo-treated subjects, respectively). Schizophrenia Trials Based on the pooled data from the three placebo-controlled, 6-week, fixed-dose studies in adult subjects with schizophrenia, among the adverse reactions that occurred with a greater than 2% incidence in the subjects treated with INVEGA ® , the incidences of the following adverse reactions increased with dose: somnolence, orthostatic hypotension, akathisia, dystonia, extrapyramidal disorder, hypertonia, parkinsonism, and salivary hypersecretion. For most of these, the increased incidence was seen primarily at the 12 mg dose, and, in some cases, the 9 mg dose. In the 6-week, fixed-dose, placebo-controlled study in adolescents with schizophrenia, among the adverse reactions that occurred with >2% incidence in the subjects treated with INVEGA ® , the incidences of the following adverse reactions increased with dose: tachycardia, akathisia, extrapyramidal symptoms, somnolence, and headache. Schizoaffective Disorder Trials In a placebo-controlled, 6-week, high- and low-dose study in adult subjects with schizoaffective disorder, akathisia, dystonia, dysarthria, myalgia, nasopharyngitis, rhinitis, cough, and pharyngolaryngeal pain occurred more frequently (i.e., a difference of at least 2%) in subjects who received higher doses of INVEGA ® compared with subjects who received lower doses. An examination of population subgroups in the three placebo-controlled, 6-week, fixed-dose studies in adult subjects with schizophrenia and in the two placebo-controlled, 6-week studies in adult subjects with schizoaffective disorder did not reveal any evidence of clinically relevant differences in safety on the basis of gender or race alone; there was also no difference on the basis of age [see Use in Specific Populations (8.5) ] . Pooled data from the three placebo-controlled, 6-week, fixed-dose studies in adult subjects with schizophrenia provided information regarding treatment-emergent EPS. Several methods were used to measure EPS: (1) the Simpson-Angus global score (mean change from baseline) which broadly evaluates Parkinsonism, (2) the Barnes Akathisia Rating Scale global clinical rating score (mean change from baseline) which evaluates akathisia, (3) use of anticholinergic medications to treat emergent EPS ( Table 7 ), and (4) incidence of spontaneous reports of EPS ( Table 8 ). For the Simpson-Angus Scale, spontaneous EPS reports and use of anticholinergic medications, there was a dose-related increase observed for the 9 mg and 12 mg doses. There was no difference observed between placebo and INVEGA ® 3 mg and 6 mg doses for any of these EPS measures. Table 7. Treatment-Emergent Extrapyramidal Symptoms (EPS) Assessed by Incidence of Ratings Scales and Use of Anticholinergic Medication – Schizophrenia Studies in Adults Percentage of Patients INVEGA ® Placebo 3 mg once daily 6 mg once daily 9 mg once daily 12 mg once daily EPS Group (N=355) (N=127) (N=235) (N=246) (N=242) Parkinsonism * 9 11 3 15 14 Akathisia † 6 6 4 7 9 Use of anticholinergic medications ‡ 10 10 9 22 22 For Parkinsonism, percent of patients with Simpson-Angus global score > 0.3 (Global score defined as total sum of items score divided by the number of items) For Akathisia, percent of patients with Barnes Akathisia Rating Scale global score ≥ 2 Percent of patients who received anticholinergic medications to treat emergent EPS Table 8. Treatment-Emergent Extrapyramidal Symptoms (EPS)-Related Adverse Events by MedDRA Preferred Term – Schizophrenia Studies in Adults Percentage of Patients INVEGA ® Placebo 3 mg once daily 6 mg once daily 9 mg once daily 12 mg once daily EPS Group (N=355) (N=127) (N=235) (N=246) (N=242) Overall percentage of patients with EPS-related AE 11 13 10 25 26 Dyskinesia 3 5 3 8 9 Dystonia 1 1 1 5 5 Hyperkinesia 4 4 3 8 10 Parkinsonism 2 3 3 7 6 Tremor 3 3 3 4 3 Compared to data from the studies in adults subjects with schizophrenia, pooled data from the two placebo-controlled 6-week studies in adult subjects with schizoaffective disorder showed similar types and frequencies of EPS as measured by rating scales, anticholinergic medication use, and spontaneous reports of EPS-related adverse events. For subjects with schizoaffective disorder, there was no dose-related increase in EPS observed for parkinsonism with the Simpson-Angus scale or akathisia with the Barnes Akathisia Rating Scale. There was a dose-related increase observed with spontaneous EPS reports of hyperkinesia and dystonia and in the use of anticholinergic medications. Table 9 shows the EPS data from the pooled schizoaffective disorder trials. Table 9. Treatment-Emergent Extrapyramidal Symptoms (EPS)-Related Adverse Events by MedDRA Preferred Term – Schizoaffective Disorder Studies in Adults Percentage of Patients INVEGA ® Placebo 3–6 mg once-daily fixed-dose range 9–12 mg once-daily fixed-dose range 3–12 mg once-daily flexible dose EPS Group (N=202) (N=108) (N=98) (N=214) Overall percentage of patients with EPS-related AE 11 23 22 17 Dyskinesia 1 3 1 1 Dystonia 1 2 3 2 Hyperkinesia 5 5 8 7 Parkinsonism 3 14 7 7 Tremor 3 12 11 5 The incidences of EPS-related adverse events in the adolescent schizophrenia studies showed a similar dose-related pattern to those in the adult studies. There were notably higher incidences of dystonia, hyperkinesia, tremor, and parkinsonism in the adolescent population as compared to the adult studies (Table 10) . Table 10. Treatment-Emergent Extrapyramidal Symptoms (EPS)-Related Adverse Events by MedDRA Preferred Term – Schizophrenia Studies in Adolescent Subjects Percentage of Patients INVEGA ® Placebo 1.5 mg once daily 3 mg once daily 6 mg once daily 12 mg once daily EPS Group (N=51) (N=54) (N=16) (N=45) (N=35) Overall percentage of patients with EPS-related AE 0 6 25 22 40 Hyperkinesia 0 4 6 11 17 Dystonia 0 2 0 11 14 Tremor 0 2 6 7 11 Parkinsonism 0 0 6 2 14 Dyskinesia 0 2 6 2 6 Dystonia Class Effect: Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic drugs. An elevated risk of acute dystonia is observed in males and younger age groups. In the pooled data from the three placebo-controlled, 6-week, fixed-dose studies in adult subjects with schizophrenia and from the two placebo-controlled, 6-week studies in adult subjects with schizoaffective disorder, between-group comparisons revealed no medically important differences between INVEGA ® and placebo in the proportions of subjects experiencing potentially clinically significant changes in routine serum chemistry, hematology, or urinalysis parameters. Similarly, there were no differences between INVEGA ® and placebo in the incidence of discontinuations due to changes in hematology, urinalysis, or serum chemistry, including mean changes from baseline in fasting glucose, insulin, c-peptide, triglyceride, HDL, LDL, and total cholesterol measurements. However, INVEGA ® was associated with increases in serum prolactin [see Warnings and Precautions (5.7) ]. The following additional adverse reactions occurred in < 2% of INVEGA ® -treated subjects in the above schizophrenia and schizoaffective disorder clinical trial datasets. The following also includes additional adverse reactions reported at any frequency by INVEGA ® -treated subjects who participated in other clinical studies. Cardiac disorders: bradycardia, palpitations Eye disorders: eye movement disorder Gastrointestinal disorders: flatulence General disorders: edema Immune system disorders: anaphylactic reaction Infections and infestations: urinary tract infection Investigations: alanine aminotransferase increased, aspartate aminotransferase increased Musculoskeletal and connective tissue disorders: arthralgia, pain in extremity Nervous system disorders: opisthotonus Psychiatric disorders: agitation, insomnia, nightmare Reproductive system and breast disorders: breast discomfort, menstruation irregular, retrograde ejaculation Respiratory, thoracic and mediastinal disorders: nasal congestion Skin and subcutaneous tissue disorders: pruritus, rash Vascular disorders: hypertension The safety of INVEGA ® was also evaluated in a long-term trial designed to assess the maintenance of effect with INVEGA ® in adults with schizophrenia [see Clinical Studies (14) ] . In general, adverse reaction types, frequencies, and severities during the initial 14-week open-label phase of this study were comparable to those observed in the 6-week, placebo-controlled, fixed-dose studies. Adverse reactions reported during the long-term double-blind phase of this study were similar in type and severity to those observed in the initial 14-week open-label phase. The following adverse reactions have been identified during postapproval use of INVEGA ® ; because these reactions were reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency: angioedema, priapism, swollen tongue, tardive dyskinesia, urinary incontinence, urinary retention. Paliperidone is the major active metabolite of risperidone. Adverse reactions reported with risperidone can be found in the ADVERSE REACTIONS section of the risperidone package insert.
adverse reactions table
<table width="85%"> <caption>Table 4. Adverse Reactions Reported by ≥ 2% of INVEGA <sup>®</sup>-Treated Adult Subjects with Schizophrenia in Three Short-Term, Fixed-Dose, Placebo-Controlled Clinical Trials <linkHtml href="#footnote-1">*</linkHtml> </caption> <col span="1" align="left" valign="top" width="30%"/> <col span="1" align="center" valign="top" width="14%"/> <col span="1" align="center" valign="top" width="14%"/> <col span="1" align="center" valign="top" width="14%"/> <col span="1" align="center" valign="top" width="14%"/> <col span="1" align="center" valign="top" width="14%"/> <tbody> <tr> <th colspan="1"/> <th colspan="5"> Percentage of Patients </th> </tr> <tr> <th colspan="1"/> <th colspan="1"/> <th colspan="4"> INVEGA <sup>®</sup> </th> </tr> <tr> <th colspan="1"/> <th colspan="1">Placebo</th> <th colspan="1">3 mg once daily</th> <th colspan="1">6 mg once daily</th> <th colspan="1">9 mg once daily</th> <th colspan="1">12 mg once daily</th> </tr> <tr> <th colspan="1">Body System or Organ Class</th> <th colspan="1">(N=355)</th> <th colspan="1">(N=127)</th> <th colspan="1">(N=235)</th> <th colspan="1">(N=246)</th> <th colspan="1">(N=242)</th> </tr> <tr> <th colspan="1"> Dictionary-Derived Term</th> <th colspan="1"/> <th colspan="1"/> <th colspan="1"/> <th colspan="1"/> <th colspan="1"/> </tr> <tr> <td> <content styleCode="bold">Total percentage of subjects with adverse reactions</content> </td> <td>37</td> <td>48</td> <td>47</td> <td>53</td> <td>59</td> </tr> <tr> <td> <content styleCode="bold"> Cardiac disorders </content> </td> <td/> <td/> <td/> <td/> <td/> </tr> <tr> <td> Atrioventricular block first degree</td> <td>1</td> <td>2</td> <td>0</td> <td>2</td> <td>1</td> </tr> <tr> <td> Bundle branch block</td> <td>2</td> <td>3</td> <td>1</td> <td>3</td> <td><1</td> </tr> <tr> <td> Sinus arrhythmia</td> <td>0</td> <td>2</td> <td>1</td> <td>1</td> <td><1</td> </tr> <tr> <td> Tachycardia</td> <td>7</td> <td>14</td> <td>12</td> <td>12</td> <td>14</td> </tr> <tr> <td> <content styleCode="bold"> Gastrointestinal disorders </content> </td> <td/> <td/> <td/> <td/> <td/> </tr> <tr> <td> Abdominal pain upper</td> <td>1</td> <td>1</td> <td>3</td> <td>2</td> <td>2</td> </tr> <tr> <td> Dry mouth</td> <td>1</td> <td>2</td> <td>3</td> <td>1</td> <td>3</td> </tr> <tr> <td> Salivary hypersecretion</td> <td><1</td> <td>0</td> <td><1</td> <td>1</td> <td>4</td> </tr> <tr> <td> <content styleCode="bold"> General disorders </content> </td> <td/> <td/> <td/> <td/> <td/> </tr> <tr> <td> Asthenia</td> <td>1</td> <td>2</td> <td><1</td> <td>2</td> <td>2</td> </tr> <tr> <td> Fatigue</td> <td>1</td> <td>2</td> <td>1</td> <td>2</td> <td>2</td> </tr> <tr> <td> <content styleCode="bold"> Nervous system disorders </content> </td> <td/> <td/> <td/> <td/> <td/> </tr> <tr> <td> Akathisia</td> <td>4</td> <td>4</td> <td>3</td> <td>8</td> <td>10</td> </tr> <tr> <td> Dizziness</td> <td>4</td> <td>6</td> <td>5</td> <td>4</td> <td>5</td> </tr> <tr> <td> Extrapyramidal symptoms</td> <td>8</td> <td>10</td> <td>7</td> <td>20</td> <td>18</td> </tr> <tr> <td> Headache</td> <td>12</td> <td>11</td> <td>12</td> <td>14</td> <td>14</td> </tr> <tr> <td> Somnolence</td> <td>7</td> <td>6</td> <td>9</td> <td>10</td> <td>11</td> </tr> <tr> <td> <content styleCode="bold"> Vascular disorders </content> </td> <td/> <td/> <td/> <td/> <td/> </tr> <tr> <td> Orthostatic hypotension</td> <td>1</td> <td>2</td> <td>1</td> <td>2</td> <td>4</td> </tr> </tbody> </table>
adverse reactions table
<table width="85%"> <caption>Table 5. Adverse Reactions Reported by ≥ 2% of INVEGA <sup>®</sup>-Treated Adolescent Subjects with Schizophrenia in a Fixed-Dose, Placebo-Controlled Clinical Trial <linkHtml href="#footnote-1">*</linkHtml> </caption> <col span="1" align="left" valign="top" width="30%"/> <col span="1" align="center" valign="top" width="14%"/> <col span="1" align="center" valign="top" width="14%"/> <col span="1" align="center" valign="top" width="14%"/> <col span="1" align="center" valign="top" width="14%"/> <col span="1" align="center" valign="top" width="14%"/> <tbody> <tr> <th colspan="1"/> <th colspan="5">Percentage of Patients</th> </tr> <tr> <th colspan="1"/> <th colspan="1"/> <th colspan="4">INVEGA <sup>®</sup> </th> </tr> <tr> <th colspan="1"/> <th colspan="1">Placebo</th> <th colspan="1">1.5 mg once daily</th> <th colspan="1">3 mg once daily</th> <th colspan="1">6 mg once daily</th> <th colspan="1">12 mg once daily</th> </tr> <tr> <th colspan="1">Body System or Organ Class</th> <th colspan="1">(N=51)</th> <th colspan="1">(N=54)</th> <th colspan="1">(N=16)</th> <th colspan="1">(N=45)</th> <th colspan="1">(N=35)</th> </tr> <tr> <th colspan="1"> Dictionary-Derived Term</th> <th colspan="1"/> <th colspan="1"/> <th colspan="1"/> <th colspan="1"/> <th colspan="1"/> </tr> <tr> <td> <content styleCode="bold">Total percentage of subjects with adverse reactions</content> </td> <td>43</td> <td>37</td> <td>50</td> <td>58</td> <td>74</td> </tr> <tr> <td> <content styleCode="bold">Cardiac disorders</content> </td> <td/> <td/> <td/> <td/> <td/> </tr> <tr> <td> Tachycardia</td> <td>0</td> <td>0</td> <td>6</td> <td>9</td> <td>6</td> </tr> <tr> <td> <content styleCode="bold">Eye disorders</content> </td> <td/> <td/> <td/> <td/> <td/> </tr> <tr> <td> Vision blurred</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>3</td> </tr> <tr> <td> <content styleCode="bold">Gastrointestinal disorders</content> </td> <td/> <td/> <td/> <td/> <td/> </tr> <tr> <td> Dry mouth</td> <td>2</td> <td>0</td> <td>0</td> <td>0</td> <td>3</td> </tr> <tr> <td> Salivary hypersecretion</td> <td>0</td> <td>2</td> <td>6</td> <td>2</td> <td>0</td> </tr> <tr> <td> Swollen tongue</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>3</td> </tr> <tr> <td> Vomiting</td> <td>10</td> <td>0</td> <td>6</td> <td>11</td> <td>3</td> </tr> <tr> <td> <content styleCode="bold">General disorders</content> </td> <td/> <td/> <td/> <td/> <td/> </tr> <tr> <td> Asthenia</td> <td>0</td> <td>0</td> <td>0</td> <td>2</td> <td>3</td> </tr> <tr> <td> Fatigue</td> <td>0</td> <td>4</td> <td>0</td> <td>2</td> <td>3</td> </tr> <tr> <td> <content styleCode="bold">Infections and infestations</content> </td> <td/> <td/> <td/> <td/> </tr> <tr> <td> Nasopharyngitis</td> <td>2</td> <td>4</td> <td>0</td> <td>4</td> <td>0</td> </tr> <tr> <td> <content styleCode="bold">Investigations</content> </td> <td/> <td/> <td/> <td/> <td/> </tr> <tr> <td> Weight increased</td> <td>0</td> <td>7</td> <td>6</td> <td>2</td> <td>3</td> </tr> <tr> <td> <content styleCode="bold">Nervous system disorders</content> </td> <td/> <td/> <td/> <td/> <td/> </tr> <tr> <td> Akathisia</td> <td>0</td> <td>4</td> <td>6</td> <td>11</td> <td>17</td> </tr> <tr> <td> Dizziness</td> <td>0</td> <td>2</td> <td>6</td> <td>2</td> <td>3</td> </tr> <tr> <td> Extrapyramidal symptoms</td> <td>0</td> <td>4</td> <td>19</td> <td>18</td> <td>23</td> </tr> <tr> <td> Headache</td> <td>4</td> <td>9</td> <td>6</td> <td>4</td> <td>14</td> </tr> <tr> <td> Lethargy</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>3</td> </tr> <tr> <td> Somnolence</td> <td>4</td> <td>9</td> <td>13</td> <td>20</td> <td>26</td> </tr> <tr> <td> Tongue paralysis</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>3</td> </tr> <tr> <td> <content styleCode="bold">Psychiatric disorders</content> </td> <td/> <td/> <td/> <td/> <td/> </tr> <tr> <td> Anxiety</td> <td>4</td> <td>0</td> <td>0</td> <td>2</td> <td>9</td> </tr> <tr> <td> <content styleCode="bold">Reproductive system and breast disorders</content> </td> <td/> <td/> <td/> </tr> <tr> <td> Amenorrhea</td> <td>0</td> <td>0</td> <td>6</td> <td>0</td> <td>0</td> </tr> <tr> <td> Galactorrhea</td> <td>0</td> <td>0</td> <td>0</td> <td>4</td> <td>0</td> </tr> <tr> <td> Gynecomastia</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>3</td> </tr> <tr> <td> <content styleCode="bold">Respiratory, thoracic and mediastinal disorders</content> </td> <td/> <td/> <td/> </tr> <tr> <td> Epistaxis</td> <td>0</td> <td>0</td> <td>0</td> <td>2</td> <td>0</td> </tr> </tbody> </table>
adverse reactions table
<table width="85%"> <caption>Table 6. Adverse Drug Reactions Reported by ≥ 2% of INVEGA <sup>®</sup>-Treated Adult Subjects with Schizoaffective Disorder in Two Double-Blind, Placebo-Controlled Clinical Trials <linkHtml href="#footnote-1">*</linkHtml> </caption> <col span="1" align="left" valign="top" width="40%"/> <col span="1" align="center" valign="top" width="15%"/> <col span="1" align="center" valign="top" width="15%"/> <col span="1" align="center" valign="top" width="15%"/> <col span="1" align="center" valign="top" width="15%"/> <tbody> <tr> <th colspan="1"/> <th colspan="4"> Percentage of Patients </th> </tr> <tr> <th colspan="1"/> <th colspan="1"/> <th colspan="1">INVEGA <sup>®</sup> </th> <th colspan="1">INVEGA <sup>®</sup> </th> <th colspan="1">INVEGA <sup>®</sup> </th> </tr> <tr> <th colspan="1"/> <th colspan="1">Placebo</th> <th colspan="1">3–6 mg once-daily fixed-dose range</th> <th colspan="1">9–12 mg once-daily fixed-dose range</th> <th colspan="1">3–12 mg once-daily flexible dose</th> </tr> <tr> <th colspan="1">Body System or Organ Class</th> <th colspan="1">(N=202)</th> <th colspan="1">(N=108)</th> <th colspan="1">(N=98)</th> <th colspan="1">(N=214)</th> </tr> <tr> <th colspan="1"> Dictionary-Derived Term</th> <th colspan="1"/> <th colspan="1"/> <th colspan="1"/> <th colspan="1"/> </tr> <tr> <td> <content styleCode="bold">Total percentage of subjects with adverse reactions</content> </td> <td>32</td> <td>48</td> <td>50</td> <td>43</td> </tr> <tr> <td> <content styleCode="bold"> Cardiac disorders </content> </td> <td/> <td/> <td/> <td/> </tr> <tr> <td> Tachycardia</td> <td>2</td> <td>3</td> <td>1</td> <td>2</td> </tr> <tr> <td> <content styleCode="bold"> Gastrointestinal disorders </content> </td> <td/> <td/> <td/> <td/> </tr> <tr> <td> Abdominal discomfort/Abdominal pain upper</td> <td>1</td> <td>1</td> <td>0</td> <td>3</td> </tr> <tr> <td> Constipation</td> <td>2</td> <td>4</td> <td>5</td> <td>4</td> </tr> <tr> <td> Dyspepsia</td> <td>2</td> <td>5</td> <td>6</td> <td>6</td> </tr> <tr> <td> Nausea</td> <td>6</td> <td>8</td> <td>8</td> <td>5</td> </tr> <tr> <td> Stomach discomfort</td> <td>1</td> <td>0</td> <td>1</td> <td>2</td> </tr> <tr> <td> <content styleCode="bold"> General disorders </content> </td> <td/> <td/> <td/> <td/> </tr> <tr> <td> Asthenia</td> <td>1</td> <td>3</td> <td>4</td> <td><1</td> </tr> <tr> <td> <content styleCode="bold"> Infections and Infestations </content> </td> <td/> <td/> <td/> <td/> </tr> <tr> <td> Nasopharyngitis</td> <td>1</td> <td>2</td> <td>5</td> <td>3</td> </tr> <tr> <td> Rhinitis</td> <td>0</td> <td>1</td> <td>3</td> <td>1</td> </tr> <tr> <td> Upper respiratory tract infection</td> <td>1</td> <td>2</td> <td>2</td> <td>2</td> </tr> <tr> <td> <content styleCode="bold"> Investigations </content> </td> <td/> <td/> <td/> <td/> </tr> <tr> <td> Weight increased</td> <td>1</td> <td>5</td> <td>4</td> <td>4</td> </tr> <tr> <td> <content styleCode="bold"> Metabolism and nutrition disorders </content> </td> <td/> <td/> <td/> <td/> </tr> <tr> <td> Decreased appetite</td> <td><1</td> <td>1</td> <td>0</td> <td>2</td> </tr> <tr> <td> Increased appetite</td> <td><1</td> <td>3</td> <td>2</td> <td>2</td> </tr> <tr> <td> <content styleCode="bold"> Musculoskeletal and connective tissue disorders </content> </td> <td/> <td/> <td/> <td/> </tr> <tr> <td> Back pain</td> <td>1</td> <td>1</td> <td>1</td> <td>3</td> </tr> <tr> <td> Myalgia</td> <td><1</td> <td>2</td> <td>4</td> <td>1</td> </tr> <tr> <td> <content styleCode="bold"> Nervous system disorders </content> </td> <td/> <td/> <td/> <td/> </tr> <tr> <td> Akathisia</td> <td>4</td> <td>4</td> <td>6</td> <td>6</td> </tr> <tr> <td> Dysarthria</td> <td>0</td> <td>1</td> <td>4</td> <td>2</td> </tr> <tr> <td> Extrapyramidal symptoms</td> <td>8</td> <td>20</td> <td>17</td> <td>12</td> </tr> <tr> <td> Somnolence</td> <td>5</td> <td>12</td> <td>12</td> <td>8</td> </tr> <tr> <td> <content styleCode="bold"> Psychiatric disorders </content> </td> <td/> <td/> <td/> <td/> </tr> <tr> <td> Sleep disorder</td> <td><1</td> <td>2</td> <td>3</td> <td>0</td> </tr> <tr> <td> <content styleCode="bold"> Respiratory, thoracic and mediastinal disorders </content> </td> <td/> <td/> <td/> <td/> </tr> <tr> <td> Cough</td> <td>1</td> <td>1</td> <td>3</td> <td>1</td> </tr> <tr> <td> Pharyngolaryngeal pain</td> <td><1</td> <td>0</td> <td>2</td> <td>1</td> </tr> </tbody> </table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.